{
  "docId": "019de516-01ce-701d-bd9b-acac15fa9fab",
  "docSlug": "a13be9775a99db49a0c5c2ac3ee2ea88",
  "documentTitle": "Oculis | Investor Conference Presentation Deck | 39 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 39,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de516-01ce-701d-bd9b-acac15fa9fab/20",
  "deckHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab",
  "deckJsonHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab.json",
  "deckAnchorHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.43,
        "w": 0.69,
        "x": 0.26,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "N = 350-450 per trial\n52 weeks\nOCS-01: 6x/day weeks 1 - 6; 3x/day weeks 7 - 52\nVehicle: 6x/day weeks 1 - 6; 3x/day weeks 7 - 52\nEnd of Trial\nWashout (if needed): 3 - 6 months depending on prior treatment\n1:1 Randomization\n6-week loading phase followed by 46-week maintenance phase\nAssessments at baseline, weeks 2, 4, 8, 16, 24, 36 and 52",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "285874e9-6c61-479a-a6b4-898a35d45038",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.33,
        "w": 0.22,
        "x": 0.039,
        "y": 0.19
      },
      "kind": "list",
      "text": "Key Enrollment Criteria\nAge 18-85 years\nNo participation in Stage 1\nConfirmed diagnosis of DME\nDiabetes mellitus 1 and 2\nETDRS BCVA letter score: 24-65\nRetinal thickness (CST) ≥ 310 μm\nAnti-VEGF and corticosteroid naïve or agree to washout",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "489fad34-4093-4eea-ae64-ffb069561a97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.44,
        "x": 0.04,
        "y": 0.69
      },
      "kind": "list",
      "text": "Endpoints\n1º endpoint: Change in BCVA ETDRS letter score at wk 52\nKey 2º endpoint: % with ≥ 3-line gain in BCVA at wk 52\n2º endpoint: Change in CST as measured by SD-OCT(1) at wk 52",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ca9037f-1761-4256-84e4-5d726e73491d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.22,
        "x": 0.527,
        "y": 0.69
      },
      "kind": "list",
      "text": "Anticipated Timelines\nStage 2 Start: 2H 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "995a9b76-32b6-41df-841d-48e15bda21eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.01,
        "w": 0.208,
        "x": 0.026,
        "y": 0.955
      },
      "kind": "source-note",
      "text": "(1) Spectral Domain Optical Coherence Tomography",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1272383-b16b-4616-8468-292c50f67537",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.022,
        "w": 0.95,
        "x": 0.026,
        "y": 0.09
      },
      "kind": "title",
      "text": "Two global Ph 3 trials (N = 350-450 each) to support NDA filing for treatment of DME",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "797b4660-aba0-4d51-bf4b-453764c4be97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.036,
        "w": 0.69,
        "x": 0.026,
        "y": 0.05
      },
      "kind": "title",
      "text": "OCS-01 Next Step: Phase 3 DME Trial Stage 2",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "204a77fc-b4ee-4b7e-872d-69e943846f81",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "b8908f27-29af-404c-ae57-65299689c6f3",
      "evidence": "The slide uses bullet points to present information about the trial, including enrollment criteria and endpoints.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 17,
      "beatId": "47165210-81f8-47ad-ae3f-2582e7380461",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 17-24 outline OCS-01's potential and the Phase 3 program.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}